New hope for hard-to-treat breast cancer: drug combo targets resistant tumors

NCT ID NCT05076682

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Jun 14, 2026 · Updated 26 times

Summary

This study tests a mix of several drugs (including sodium cromoglicate, choline, efavirenz, and others) combined with an immune checkpoint inhibitor in people with advanced triple-negative breast cancer whose tumors stopped responding to immunotherapy. The goal is to see if the combination can shrink tumors or slow the disease. About 80 participants will be enrolled at one site in China.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

TRIPLE NEGATIVE BREAST CANCER